Morino Yoshihiro, Kaneda Hideaki, Fox Tim, Takagi Atsushi, Hassan Ali H M, Bonan Raoul, Crocker Ian, Lansky Alexandra J, Laskey Warren K, Suntharalingam Mohan, Bonneau Heidi N, Yock Paul G, Honda Yasuhiro, Fitzgerald Peter J
Center for Research in Cardiovascular Interventions, Stanford University Medical Center, Stanford, Calif 94305-5637, USA.
Circulation. 2002 Oct 29;106(18):2334-9. doi: 10.1161/01.cir.0000036367.17043.03.
Observations from previous intracoronary radiation therapy trials noted a considerable discrepancy between the prescribed radiation dose and the dose actually delivered. The aims of this study were to investigate the effect of actual delivered dose on vascular changes and to test the appropriateness of the current dose prescription.
Serial volumetric intravascular ultrasound (IVUS) analysis was performed in 30 in-stent restenosis cases treated with a 40-mm (90)Sr/Y source train. The fixed dose was prescribed at 2 mm from the centerline of the source train (18.4 Gy at 2 mm for reference diameter < or =3.35 mm and 23 Gy for diameter > or =3.36 mm). Only stent segments with full radiation coverage and device injury were enrolled and divided into 2-mm-long subsegments (n=202). D(S90)EEM (the minimum dose absorbed by 90% of the external elastic membrane surface) was calculated as the delivered dose corresponding to each segment, assuming that the radiation catheter occupied the same position in the vessel as the IVUS catheter. Mean D(S90)EEM of 23.5+/-5.82 Gy (range 12.3 to 41.7 Gy) was delivered to these subsegments. Overall, intimal hyperplasia volume remained constant from postintervention to follow-up (2.23+/-1.10 to 2.32+/-1.09 mm3/m; P=NS). Regression analysis revealed there was no correlation between delivered dose intensity and changes in intimal hyperplasia volume. No particular dose-dependent complications were appreciated in this delivered dose range.
The current dose-prescription protocol of (90)Sr/Y radiation to native in-stent restenosis lesions may provide substantial inhibition of neointimal reproliferation regardless of the actual delivered dose intensity.
先前冠状动脉内放射治疗试验的观察结果表明,规定的放射剂量与实际给予的剂量之间存在相当大的差异。本研究的目的是调查实际给予剂量对血管变化的影响,并测试当前剂量处方的适宜性。
对30例接受40毫米(90)锶/钇源导管治疗的支架内再狭窄病例进行了连续的血管内超声(IVUS)容积分析。固定剂量规定在距源导管中心线2毫米处(参考直径≤3.35毫米时2毫米处为18.4戈瑞,直径≥3.36毫米时为23戈瑞)。仅纳入具有完整放射覆盖和器械损伤的支架节段,并将其分为2毫米长的子节段(n = 202)。假设放射导管在血管中的位置与IVUS导管相同,计算每个节段对应的吸收剂量D(S90)EEM(90%的外弹力膜表面吸收的最小剂量)。这些子节段的平均D(S90)EEM为23.5±5.82戈瑞(范围为12.3至41.7戈瑞)。总体而言,从干预后到随访时内膜增生体积保持不变(2.23±1.10至2.32±1.09立方毫米/米;P =无显著差异)。回归分析显示,给予剂量强度与内膜增生体积变化之间无相关性。在该给予剂量范围内未发现特定的剂量依赖性并发症。
当前对天然支架内再狭窄病变进行(90)锶/钇放射的剂量处方方案,可能无论实际给予剂量强度如何,都能对新生内膜再增殖提供显著抑制。